SPAR
MCID: SPS226
MIFTS: 37

Spastic Paraplegia, Ataxia, and Mental Retardation (SPAR)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Spastic Paraplegia, Ataxia, and Mental Retardation

MalaCards integrated aliases for Spastic Paraplegia, Ataxia, and Mental Retardation:

Name: Spastic Paraplegia, Ataxia, and Mental Retardation 56 71
Spar 56 74
Spare 17

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
highly variable phenotype


HPO:

31
spastic paraplegia, ataxia, and mental retardation:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Spastic Paraplegia, Ataxia, and Mental Retardation

MalaCards based summary : Spastic Paraplegia, Ataxia, and Mental Retardation, also known as spar, is related to nonaka myopathy and partial third-nerve palsy, and has symptoms including ataxia and urgency of micturition. The drugs Etoposide and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and bone, and related phenotypes are intellectual disability and hyperreflexia

More information from OMIM: 607565

Related Diseases for Spastic Paraplegia, Ataxia, and Mental Retardation

Diseases related to Spastic Paraplegia, Ataxia, and Mental Retardation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1582)
# Related Disease Score Top Affiliating Genes
1 nonaka myopathy 12.1
2 partial third-nerve palsy 11.5
3 inclusion body myositis 11.5
4 medulloblastoma 11.3
5 undifferentiated pleomorphic sarcoma 11.3
6 facioscapulohumeral muscular dystrophy 1 11.3
7 epiphyseal dysplasia, multiple, 2 11.3
8 telangiectasia macularis eruptive perstans 11.3
9 schnyder corneal dystrophy 11.1
10 liddle syndrome 1 11.1
11 tracheopathia osteoplastica 11.1
12 fleck retina, familial benign 11.1
13 hypotrichosis 8 11.1
14 hypotrichosis 6 11.1
15 macular dystrophy with central cone involvement 11.1
16 adiposis dolorosa 11.0
17 palmoplantar keratoderma and congenital alopecia 1 11.0
18 anonychia-onychodystrophy with hypoplasia or absence of distal phalanges 11.0
19 digital clubbing, isolated congenital 11.0
20 camurati-engelmann disease 11.0
21 epidermolysis bullosa dystrophica, pretibial 11.0
22 erythermalgia, primary 11.0
23 nail disorder, nonsyndromic congenital, 1 11.0
24 otodental dysplasia 11.0
25 leukodystrophy, demyelinating, adult-onset, autosomal dominant 11.0
26 palmoplantar keratoderma and congenital alopecia 2 11.0
27 macular dystrophy, corneal 11.0
28 laurence-moon syndrome 11.0
29 miyoshi muscular dystrophy 1 11.0
30 retinal dystrophy, reticular pigmentary, of posterior pole 11.0
31 charcot-marie-tooth disease, x-linked dominant, 1 11.0
32 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 11.0
33 amyotrophic lateral sclerosis 4, juvenile 11.0
34 limb-mammary syndrome 11.0
35 encephalopathy, familial, with neuroserpin inclusion bodies 11.0
36 bartter syndrome, type 3 11.0
37 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 11.0
38 lipodystrophy, partial, acquired 11.0
39 spinocerebellar ataxia 26 11.0
40 epidermolysis bullosa simplex with migratory circinate erythema 11.0
41 myasthenic syndrome, congenital, 12 11.0
42 lipodystrophy, partial, acquired, with low complement component c3, with or without glomerulonephritis 11.0
43 nevoid hypermelanosis, linear and whorled 11.0
44 osteosclerotic metaphyseal dysplasia 11.0
45 retinal dystrophy, juvenile cataracts, and short stature syndrome 11.0
46 pontocerebellar hypoplasia, type 1d 11.0
47 erythrokeratodermia variabilis et progressiva 6 11.0
48 acquired generalized lipodystrophy 11.0
49 sympathetic ophthalmia 11.0
50 critical illness polyneuropathy 11.0

Graphical network of the top 20 diseases related to Spastic Paraplegia, Ataxia, and Mental Retardation:



Diseases related to Spastic Paraplegia, Ataxia, and Mental Retardation

Symptoms & Phenotypes for Spastic Paraplegia, Ataxia, and Mental Retardation

Human phenotypes related to Spastic Paraplegia, Ataxia, and Mental Retardation:

31 (show all 17)
# Description HPO Frequency HPO Source Accession
1 intellectual disability 31 HP:0001249
2 hyperreflexia 31 HP:0001347
3 abnormality of eye movement 31 HP:0000496
4 ataxia 31 HP:0001251
5 dysarthria 31 HP:0001260
6 babinski sign 31 HP:0003487
7 urinary bladder sphincter dysfunction 31 HP:0002839
8 dystonia 31 HP:0001332
9 spastic paraplegia 31 HP:0001258
10 cerebellar atrophy 31 HP:0001272
11 lower limb muscle weakness 31 HP:0007340
12 impaired vibration sensation in the lower limbs 31 HP:0002166
13 ankle clonus 31 HP:0011448
14 urinary urgency 31 HP:0000012
15 spastic gait 31 HP:0002064
16 urinary incontinence 31 HP:0000020
17 knee clonus 31 HP:0011449

Symptoms via clinical synopsis from OMIM:

56
Neurologic Central Nervous System:
hyperreflexia
ataxia
dysarthria
dystonia
cerebellar atrophy
more
Head And Neck Eyes:
abnormal extraocular movements

Genitourinary Bladder:
urinary urgency
urinary incontinence
sphincter disturbances

Clinical features from OMIM:

607565

UMLS symptoms related to Spastic Paraplegia, Ataxia, and Mental Retardation:


ataxia, urgency of micturition

Drugs & Therapeutics for Spastic Paraplegia, Ataxia, and Mental Retardation

Drugs for Spastic Paraplegia, Ataxia, and Mental Retardation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4 33419-42-0 36462
2
Idarubicin Approved Phase 4 58957-92-9 42890
3
Magnesium citrate Approved Phase 4 3344-18-1
4
Magnesium oxide Approved Phase 4 1309-48-4 14792
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
leucovorin Approved Phase 4 58-05-9 6006 143
7
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
8
Bevacizumab Approved, Investigational Phase 4 216974-75-3
9
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
10
Parecoxib Approved Phase 4 198470-84-7
11
Clonidine Approved Phase 4 4205-90-7 2803
12
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
13
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
14
Cefoxitin Approved Phase 4 35607-66-0 441199
15
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
16
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
17
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
18
Levulinic acid Experimental Phase 4 123-76-2 11579
19 Gastrointestinal Agents Phase 4
20 Etoposide phosphate Phase 4
21 Anti-Anxiety Agents Phase 4
22 Pharmaceutical Solutions Phase 4
23 Polyethylene glycol 3350 Phase 4
24 Cathartics Phase 4
25 Citrate Phase 4
26 Anticoagulants Phase 4
27 Laxatives Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Analgesics Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Cyclooxygenase Inhibitors Phase 4
33 Cyclooxygenase 2 Inhibitors Phase 4
34 Neurotransmitter Agents Phase 4
35 Autonomic Agents Phase 4
36 Antihypertensive Agents Phase 4
37 Adrenergic Agonists Phase 4
38 Adrenergic alpha-2 Receptor Agonists Phase 4
39 Adrenergic Agents Phase 4
40 Sympatholytics Phase 4
41 Anti-Infective Agents Phase 4
42 HIV Protease Inhibitors Phase 4
43
protease inhibitors Phase 4
44 Anti-Bacterial Agents Phase 4
45 Antibiotics, Antitubercular Phase 4
46
Epirubicin Approved Phase 3 56420-45-2 41867
47
Dexmedetomidine Approved, Vet_approved Phase 3 113775-47-6 68602 5311068
48
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
49
deoxycholic acid Approved Phase 3 83-44-3 222528
50
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965

Interventional clinical trials:

(show top 50) (show all 271)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
2 A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy Unknown status NCT01657812 Phase 4 dexmedetomidine
3 Improving Cone-beam Computed Tomography for Image Guided Stereotactic Body Radiation Therapy of the Liver Using Gadoxetate Disodium Unknown status NCT03215355 Phase 4 Primovist
4 COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
5 The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease Completed NCT00994006 Phase 4
6 Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic Completed NCT01050556 Phase 4
7 Effectiveness of Topical Negative Handicraft Device for Versus Traditional Conservative Treatment in Skin Ulcers Management in Lower Limb Completed NCT02512159 Phase 4
8 Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions Completed NCT00978939 Phase 4
9 Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study Completed NCT00247338 Phase 4 low calorie, low nitrogen parenteral nutrition for patient with NRS score 3
10 A Study to Evaluate Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib Post Total Knee Arthroplasty in Osteoarthritis Patients Completed NCT02198924 Phase 4 Parecoxib and Celecoxib;placebo
11 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
12 Clinical Outcome Following Arthroscopic Knee Surgery (COFAKS)-Addendum Active, not recruiting NCT03704376 Phase 4 30 ml of 0.2% ropivacaine;15 ml of 0.2% ropivacaine;100 mcg clonidine
13 Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli Terminated NCT02474706 Phase 4 Cefoxitin;imipenem
14 The Efficacy and Safety of Sanfujiu on Patients With Persistent Allergic Rhinitis: Randomized Controlled Study (SPAR Study) Unknown status NCT02192645 Phase 3 Sanfujiu;Placebo
15 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
16 Bone Sparing Effects of Soy Phytoestrogens in Menopause Completed NCT00076050 Phase 3
17 Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer Completed NCT01049425 Phase 3 Epirubicin;Cyclophosphamide;Docetaxel;Cyclophosphamide;Docetaxel
18 Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
19 Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence Completed NCT01166438 Phase 3 Botulinum toxin A (Botox A®);Solifenacin 5mg;Solifenacin 10mg;Trospium chloride
20 Submacular Surgery Trials (SST) Completed NCT00000150 Phase 3
21 A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping Completed NCT01106040 Phase 3 Lymphoseek
22 A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping Completed NCT00671918 Phase 3 Lymphoseek
23 Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal Surgery Completed NCT01353456 Phase 3 Dexmedetomidine;Normal Saline
24 ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping Recruiting NCT03927027 Phase 3 Isosulfan Blue
25 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Recruiting NCT03263715 Phase 3 Tocilizumab Prefilled Syringe [Actemra];Placebos;Glucocorticoids
26 To Demonstrate the Ability of Abatacept in Comparison to Placebo to Obtain a Low Disease Activity [PMR-AS (CRP) Lower or Equal to 10] Without GCs (Prednisone or Prednisolone) at Week 12 in Early Onset PMR Patients. Recruiting NCT03632187 Phase 3 Abatacept;Placebos
27 Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia Active, not recruiting NCT01874587 Phase 3
28 Multicenter Randomized Phase III Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: a DaRenCa and NoRenCa Trial Evaluating the Impact of Surgery or No Surgery. The NORDIC-SUN-Trial Not yet recruiting NCT03977571 Phase 3 Nivolumab;Ipilimumab
29 Refractory Urge Incontinence and Botox Injections Terminated NCT00373789 Phase 3 Botulinum Toxin A, bladder detrusor muscle injection;Vehicle saline as placebo
30 Phase 2 Study: Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases Unknown status NCT01861873 Phase 2
31 Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial) Unknown status NCT00503178 Phase 2
32 A Phase II Study of Stereotactic Body Radiation Therapy and ZADAXIN's® (Thymalfasin) Induced Tumor Effects in Patients With Heavily Pretreated, Metastatic Esophageal Cancer Unknown status NCT02545751 Phase 2 Thymalfasin
33 EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
34 A Phase I Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck Unknown status NCT02112344 Phase 1, Phase 2
35 In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma: A Feasibility Study Unknown status NCT02759536 Phase 1, Phase 2
36 A Randomized, Phase II Study of Concurrent Radiotherapy and Oxaliplatin, Capecitabine With or Without Cetuximab in Rectal Cancer Tumor Stratified by KRAS Mutation Status. Unknown status NCT00795301 Phase 2 Capecitabine, Cetuximab, Oxaliplatin
37 The Effect of Electroacupuncture Combined With Donepezil on Cognitive Function in Alzheimer's Disease Patients: Study Protocol for a Randomized Controlled Trial Unknown status NCT02305836 Phase 2 donepezil
38 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA Unknown status NCT02290613 Phase 2 Ambrisentan;Placebo
39 HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Unknown status NCT02776202 Phase 2 Fludarabine monophosphate
40 Efficacy of Oncoxin-Viusin® Nutritional Supplement Related With the Onco-specific Treatments in Prostate Cancer Patients Completed NCT03543670 Phase 2
41 Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer Completed NCT00006360 Phase 1, Phase 2 radioprotection
42 Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Completed NCT01610180 Phase 2 Eltrombopag Olamine
43 Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer Completed NCT01824329 Phase 2
44 Phase II Study of Chemo-Radiation-Induced Abscopal Effect in Metastatic Breast Cancer and in Other Metastatic Sites of Solid Tumors Completed NCT02474186 Phase 2 Xeloda;paclitaxel
45 Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging Completed NCT01717391 Phase 2 fluorothymidine F 18
46 Phase I/II Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer Completed NCT00956228 Phase 1, Phase 2
47 Recurrent Prostate Cancer After Irradiation Treated With Brachytherapy Remedial: Phase 2 Study Completed NCT01956058 Phase 2
48 TAC (Treatment Africa Hepatitis C) : Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa Completed NCT02405013 Phase 2 Sofosbuvir;Ribavirin;Sofosbuvir;Ledipasvir
49 Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) Completed NCT01228318 Phase 2 Zoledronic acid
50 Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer Completed NCT01591733 Phase 2 FOLFIRINOX;Capecitabine

Search NIH Clinical Center for Spastic Paraplegia, Ataxia, and Mental Retardation

Genetic Tests for Spastic Paraplegia, Ataxia, and Mental Retardation

Anatomical Context for Spastic Paraplegia, Ataxia, and Mental Retardation

MalaCards organs/tissues related to Spastic Paraplegia, Ataxia, and Mental Retardation:

40
Breast, Brain, Bone, Liver, Prostate, Lung, Heart

Publications for Spastic Paraplegia, Ataxia, and Mental Retardation

Articles related to Spastic Paraplegia, Ataxia, and Mental Retardation:

(show top 50) (show all 265)
# Title Authors PMID Year
1
Spastic paraplegia, ataxia, mental retardation (SPAR): a novel genetic disorder. 61 56
11839840 2002
2
Unusual nature of long non-coding RNAs coding for "unusual peptides". 61
31874196 2020
3
Impact of bonfires on soil properties in an urban park in Vilnius (Lithuania). 61
31740035 2020
4
A Software for Calculating the Economic Aspects of Floating Offshore Renewable Energies. 61
31892261 2019
5
SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. 61
31847830 2019
6
SPar-K: a method to partition NGS signal data. 61
31116370 2019
7
Will SPAR be useful in the usual patients with scleroderma? 61
30194274 2019
8
Response to: 'Will SPAR be useful in the usual patients with scleroderma?' by Chattopadhyay et al. 61
30415200 2019
9
Economic Aspects of a Concrete Floating Offshore Wind Platform in the Atlantic Arc of Europe. 61
31717702 2019
10
Response to: 'Can we further SPARkle the SPAR model?' by Kavadichanda et al. 61
30032115 2019
11
Can we further SPARkle the SPAR model? 61
29959182 2019
12
Human reliability assessment in a 99Mo/99mTc generator production facility using the standardized plant analysis risk-human (SPAR-H) technique. 61
29227214 2019
13
Using Video Processing for the Full-Field Identification of Backbone Curves in Case of Large Vibrations. 61
31117292 2019
14
Xanthoceraside prevented synaptic loss and reversed learning-memory deficits in APP/PS1 transgenic mice. 61
30767122 2019
15
Are plants used in the Eastern Cape province for cosmetics fully commercialized? 61
31391681 2019
16
Iceland spar calcite: Humidity and time effects on surface properties and their reversibility. 61
30682592 2019
17
Characterization of bubble column photobioreactors for shear-sensitive microalgae culture. 61
30572257 2019
18
Proposal of a new way to evaluate the external sphincter function prior male sling surgey. 61
30735337 2019
19
Factors Influencing Consumer Purchase Intentions of Organically Grown Products in Shelly Centre, Port Shepstone, South Africa. 61
30884921 2019
20
Finer SHM-Coverage of Inter-Plies and Bondings in Smart Composite by Dual Sinusoidal Placed Distributed Optical Fiber Sensors. 61
30759828 2019
21
Synthesis and SPAR exploration of new semicarbazone-triazole hybrids in search of potent antioxidant, antibacterial and antifungal agents. 61
30511302 2019
22
SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. 61
31281314 2019
23
High-Dose Rate Brachyther-apy in the Treatment of Early Stages of Penile Carcinoma. 61
30764630 2019
24
Social Stress-Induced Postsynaptic Hyporesponsiveness in Glutamatergic Synapses Is Mediated by PSD-Zip70-Rap2 Pathway and Relates to Anxiety-Like Behaviors. 61
31969804 2019
25
Elevated carbon dioxide and drought modulate physiology and storage-root development in sweet potato by regulating microRNAs. 61
30244303 2019
26
Genome Sequence Analysis of Two Pseudomonas putida Strains to Identify a 17-Hydroxylase Putatively Involved in Sparteine Degradation. 61
30267141 2018
27
Lead, cadmium, arsenic, and mercury combined exposure disrupted synaptic homeostasis through activating the Snk-SPAR pathway. 61
30099283 2018
28
Validity of a triaxial accelerometer and simplified physical activity record in older adults aged 64-96 years: a doubly labeled water study. 61
30019086 2018
29
Modeling and optimization of lucky nut biodiesel production from lucky nut seed by pearl spar catalysed transesterification. 61
30255160 2018
30
Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. 61
29875097 2018
31
Phosphorylation of synaptic GTPase-activating protein (synGAP) by polo-like kinase (Plk2) alters the ratio of its GAP activity toward HRas, Rap1 and Rap2 GTPases. 61
30049443 2018
32
A multi-modal relative spatial access assessment approach to measure spatial accessibility to primary care providers. 61
30139378 2018
33
Aortic valve and left ventricular outflow tract calcium volume and distribution in transcatheter aortic valve replacement: Influence on the risk of significant paravalvular regurgitation. 61
29519754 2018
34
SPAR: small RNA-seq portal for analysis of sequencing experiments. 61
29733404 2018
35
Tale of the Good and the Bad Cdk5: Remodeling of the Actin Cytoskeleton in the Brain. 61
28502042 2018
36
Solo-Surgeon Single-Port Laparoscopic Anterior Resection for Sigmoid Colon Cancer: Comparative Study. 61
28829927 2018
37
Microwave radiation leading to shrinkage of dendritic spines in hippocampal neurons mediated by SNK-SPAR pathway. 61
29180226 2018
38
Inhibition of SNK-SPAR signaling pathway promotes the restoration of motor function in a rat model of ischemic stroke. 61
28696012 2018
39
OpenBiodiv-O: ontology of the OpenBiodiv knowledge management system. 61
29347997 2018
40
Limited reliability of radiographic assessment of spinal progression in ankylosing spondylitis. 61
28968836 2017
41
Progress in long non-coding RNAs in animals. 61
29254923 2017
42
Full-Scale Fatigue Testing of a Wind Turbine Blade in Flapwise Direction and Examining the Effect of Crack Propagation on the Blade Performance. 61
28972548 2017
43
Magnocellular Bias in Exogenous Attention to Biologically Salient Stimuli as Revealed by Manipulating Their Luminosity and Color. 61
28557693 2017
44
Efficient and reproducible in vitro regeneration of Solanum lycopersicum and assessment genetic uniformity using flow cytometry and SPAR methods. 61
28855842 2017
45
The SNK and SPAR signaling pathway changes in hippocampal neurons treated with amyloid-beta peptide in vitro. 61
28400058 2017
46
SPAR, a lncRNA encoded mTORC1 inhibitor. 61
28319435 2017
47
lncRNA-Encoded Polypeptide SPAR(s) with mTORC1 to Regulate Skeletal Muscle Regeneration. 61
28388426 2017
48
Probiotic and antioxidant properties of selenium-enriched Lactobacillus brevis LSe isolated from an Iranian traditional dairy product. 61
28159215 2017
49
Short-term low-severity spring grassland fire impacts on soil extractable elements and soil ratios in Lithuania. 61
27836340 2017
50
Influence of Surface Charge Density and Morphology on the Formation of Polyelectrolyte Multilayers on Smooth Charged Cellulose Surfaces. 61
28045539 2017

Variations for Spastic Paraplegia, Ataxia, and Mental Retardation

Expression for Spastic Paraplegia, Ataxia, and Mental Retardation

Search GEO for disease gene expression data for Spastic Paraplegia, Ataxia, and Mental Retardation.

Pathways for Spastic Paraplegia, Ataxia, and Mental Retardation

GO Terms for Spastic Paraplegia, Ataxia, and Mental Retardation

Sources for Spastic Paraplegia, Ataxia, and Mental Retardation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....